316 related articles for article (PubMed ID: 34681869)
1. IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma.
Shimizu H; Hayashi M; Kato H; Nakagawa M; Imaizumi K; Okazawa M
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681869
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of eosinophilic chronic rhinosinusitis and eosinophilic otitis media using the anti-IL-5 receptor monoclonal antibody benralizumab: A case report.
Kagoshima H; Hori R; Kojima T; Okanoue Y; Taguchi A; Yamamoto H; Hasebe K; Shoji K
Respir Med Case Rep; 2020; 30():101135. PubMed ID: 32612919
[TBL] [Abstract][Full Text] [Related]
3. Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media.
Hamada S; Ogino E; Yasuba H
Allergol Int; 2021 Jul; 70(3):389-391. PubMed ID: 33685801
[No Abstract] [Full Text] [Related]
4. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
[TBL] [Abstract][Full Text] [Related]
5. Rapid and remarkable effectiveness of benralizumab for treating severe bronchial asthma with intractable eosinophilic rhinosinusitis and eosinophilic otitis media: A case report.
Shimizu H; Kato H; Yoshioka S; Okazawa M
Respir Med Case Rep; 2021; 32():101336. PubMed ID: 33489745
[TBL] [Abstract][Full Text] [Related]
6. Dupilumab improves eosinophilic otitis media associated with eosinophilic chronic rhinosinusitis.
Nakashima D; Nakayama T; Minagawa S; Adachi T; Mitsuyama C; Shida Y; Nakajima T; Haruna SI; Matsuwaki Y
Allergol Int; 2023 Oct; 72(4):557-563. PubMed ID: 37061391
[TBL] [Abstract][Full Text] [Related]
7. Real-life effects of benralizumab on allergic chronic rhinosinusitis and nasal polyposis associated with severe asthma.
Lombardo N; Pelaia C; Ciriolo M; Della Corte M; Piazzetta G; Lobello N; Viola P; Pelaia G
Int J Immunopathol Pharmacol; 2020; 34():2058738420950851. PubMed ID: 32816558
[TBL] [Abstract][Full Text] [Related]
8. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
Iino Y; Takahashi E; Ida S; Kikuchi S
Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
[TBL] [Abstract][Full Text] [Related]
9. Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study.
Detoraki A; Tremante E; D'Amato M; Calabrese C; Casella C; Maniscalco M; Poto R; Brancaccio R; Boccia M; Martino M; Imperatore C; Spadaro G
Ther Adv Respir Dis; 2021; 15():17534666211009398. PubMed ID: 33910399
[TBL] [Abstract][Full Text] [Related]
10. Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma.
Iino Y; Sekine Y; Yoshida S; Kikuchi S
Auris Nasus Larynx; 2021 Jun; 48(3):353-360. PubMed ID: 32943257
[TBL] [Abstract][Full Text] [Related]
11. [A CASE OF SEVERE ASTHMA SWITCHED TO MEPOLIZUMAB DUE TO LATE-OCCURRING UNRESPONSIVENESS TO BENRALIZUMAB].
Matsumoto-Sasaki M; Shimizu K; Suzuki M; Suzuki M; Nakamaru Y; Konno S
Arerugi; 2020; 69(8):678-682. PubMed ID: 32963191
[TBL] [Abstract][Full Text] [Related]
12. HFA-BDP Metered-Dose Inhaler Exhaled Through the Nose Improves Eosinophilic Chronic Rhinosinusitis With Bronchial Asthma: A Blinded, Placebo-Controlled Study.
Kobayashi Y; Yasuba H; Asako M; Yamamoto T; Takano H; Tomoda K; Kanda A; Iwai H
Front Immunol; 2018; 9():2192. PubMed ID: 30337921
[No Abstract] [Full Text] [Related]
13. Comparison of Sinonasal Histopathological Changes in Biological Treatment of Eosinophilic Chronic Rhinosinusitis.
Ho J; Alvarado R; Rimmer J; Sewell WA; Walter S; Earls P; Campbell RG; Sacks R; Kalish LH; Harvey RJ
Am J Rhinol Allergy; 2022 Jan; 36(1):72-80. PubMed ID: 34096329
[TBL] [Abstract][Full Text] [Related]
14. A Phase II, Multicenter, Randomized, Placebo-Controlled Study of Benralizumab, a Humanized Anti-IL-5R Alpha Monoclonal Antibody, in Patients With Eosinophilic Chronic Rhinosinusitis.
Takabayashi T; Asaka D; Okamoto Y; Himi T; Haruna S; Yoshida N; Kondo K; Yoshikawa M; Sakuma Y; Shibata K; Suzuki M; Kobayashi M; Kawata R; Tsuzuki K; Okano M; Higaki T; Takeno S; Kodama S; Yonekura S; Saito H; Nozaki A; Otori N; Fujieda S
Am J Rhinol Allergy; 2021 Nov; 35(6):861-870. PubMed ID: 33840229
[TBL] [Abstract][Full Text] [Related]
15. Role of eosinophilic chronic rhinosinusitis in switching to benralizumab treatment in mepolizumab responders.
Hamada S; Kobayashi Y; Yasuba H
Int J Clin Pharmacol Ther; 2020 Dec; 58(12):703-708. PubMed ID: 32831163
[TBL] [Abstract][Full Text] [Related]
16. Rapid Effect of Benralizumab for Hypereosinophilia in a Case of Severe Asthma with Eosinophilic Chronic Rhinosinusitis.
Tsurumaki H; Matsuyama T; Ezawa K; Koga Y; Yatomi M; Aoki-Saito H; Chikamatsu K; Hisada T
Medicina (Kaunas); 2019 Jul; 55(7):. PubMed ID: 31277327
[TBL] [Abstract][Full Text] [Related]
17. Effect of Dupilumab on Depression in Asthma with Eosinophilic Chronic Rhinosinusitis in the Japanese Population.
Koya T; Sakai N; Sasaki T; Shinbori K; Nagai A; Kimura Y; Toyama M; Hayashi M; Saito A; Nishiyama Y; Hasegawa T; Muramatsu Y; Muramatsu K; Horii A; Kikuchi T
Int Arch Allergy Immunol; 2022; 183(3):289-297. PubMed ID: 34657036
[TBL] [Abstract][Full Text] [Related]
18. Benralizumab effect on severe chronic rhinosinusitis with nasal polyps (CRSwNP): A randomized double-blind placebo-controlled trial.
Tversky J; Lane AP; Azar A
Clin Exp Allergy; 2021 Jun; 51(6):836-844. PubMed ID: 33595845
[TBL] [Abstract][Full Text] [Related]
19. Successful management of eosinophilic chronic rhinosinusitis complicated by severe asthma using dupilumab, following negative initial results with benralizumab.
Suzaki I; Tanaka A; Hirano K; Arai S; Kobayashi H
Allergol Int; 2021 Jan; 70(1):150-152. PubMed ID: 32507512
[No Abstract] [Full Text] [Related]
20. Benralizumab reduces eosinophils and inflammatory markers in patients with severe eosinophilic asthma and chronic rhinosinusitis with nasal polyps: A pilot real-life study.
Cavaliere C; Segatto M; Ciofalo A; Colizza A; Minni A; Messineo D; Lambiase A; Greco A; de Vincentiis M; Masieri S
Immunol Lett; 2022 Aug; 248():70-77. PubMed ID: 35752279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
